NICE considers treatment for breast cancer prevention

A proposed update to the National Institute for Health and Clinical Excellence's familial breast cancer clinical guideline is exploring whether hormone therapy could be given to at-risk women for up to five years to help cut their risk of getting the disease. According to the institute, for those for whom surgery is unsuitable, so-called 'chemoprevention' through drugs such as tamoxifen and raloxifene "may represent a more acceptable means of risk reduction", even though they are not licensed specifically for this use in the UK.
Source: NHS Networks - Category: UK Health Authors: Source Type: news